Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

NCT04035733 is registered in ClinicalTrials.gov with AKARI Therapeutics as lead sponsor.

NCT NCT04035733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04035733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
Lead sponsor
AKARI Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 25, 2018
Completion date
April 29, 2020
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bullous pemphigoid (bp)